<DOC>
	<DOC>NCT02754180</DOC>
	<brief_summary>Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes after curative resection.</brief_summary>
	<brief_title>Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes</brief_title>
	<detailed_description>Adjuvant Gemcitabine Versus Gemcitabine With TS-1 based Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes after curative resection: a randomized phase II study.</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically confirmed resected ductal pancreatic adenocarcinoma with R1 resection and/or positive lymph nodes. Subject should start treatment no later than 10 weeks postsurgery. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Acceptable hematology parameters: Absolute neutrophil count ≥1500 cell/mm3 Platelet count ≥100,000/mm3 Hemoglobin (Hgb) ≥8.0 g/dL Acceptable blood chemistry levels: Aspartate aminotransferase (AST) and Alanine transaminase (ALT) ≤2.5 × upper limit of normal range (ULN) Total bilirubin ≤ 2.5 x upper Limit of Normal (ULN) Serum creatinine within upper limits of normal. Cancer antigen (CA)199 ≤ 2.5 x upper Limit of Normal (ULN) assessed within 14 days of randomization. No disease recurrence or metastases detected on CT/MRI assessed within 30 days of randomization. Signed informed consent. R2 resection or presence of metastatic disease. Prior neoadjuvant treatment or radiation therapy for pancreatic adenocarcinoma. Any other malignancy within 5 years prior to randomization, with the exception of adequately treated insitu carcinoma of the cervix, uteri, bladder, or nonmelanomatous skin cancer. Active, uncontrolled infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate treatment. Severe, active comorbidity, defined as follows: Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months Transmural myocardial infarction within the 6 months of study registration Uncontrolled hypertension, diabetes or arrhythmia. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization. Not able to take medicine orally.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>adjuvant</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>R1 resection</keyword>
	<keyword>positive lymph nodes</keyword>
</DOC>